GNI Group Ltd. is a Japan-based company engaged in new drug production activities utilizing biotechnologies. The Company is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. It is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).
Ticker:
2160
ISIN:
JP3386370005
Address:
3F, Nihonbashi-Honch (click to copy or hover over here to view full address)
CSRHub includes data on CSR, Human Rights & Supply Chain, investment income, Rating disparities, Task Force for Climate Related Financial Disclosure, and ESG ratings.